Grand Pharmaceutical Group Gelecekteki Büyüme
Future kriter kontrolleri 1/6
Grand Pharmaceutical Group is forecast to grow earnings and revenue by 2.3% and 6.2% per annum respectively. EPS is expected to grow by 1.5% per annum. Return on equity is forecast to be 13% in 3 years.
Anahtar bilgiler
2.3%
Kazanç büyüme oranı
1.5%
EPS büyüme oranı
Pharmaceuticals kazanç büyümesi | 11.1% |
Gelir büyüme oranı | 6.2% |
Gelecekteki özkaynak getirisi | 13.0% |
Analist kapsamı | Low |
Son güncelleme | 22 Oct 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 19Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year
Jun 05Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings
May 22Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26
Apr 25Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26
Mar 25We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt
Oct 20Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching
Sep 26Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14
Jun 04Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?
May 05Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Nov 21Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?
Sep 05Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Aug 16Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching
Jul 28Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11
May 29Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount?
Apr 08Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet
Mar 22If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late
Jan 24These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely
Dec 13Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price
Nov 27With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting
Oct 25China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly
Sep 01Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention?
Jul 12Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
12/31/2026 | 14,034 | 2,526 | 2,135 | 2,561 | 3 |
12/31/2025 | 12,898 | 2,212 | 1,724 | 2,090 | 3 |
12/31/2024 | 11,645 | 2,039 | 1,635 | 2,178 | 3 |
6/30/2024 | 10,587 | 2,409 | 1,451 | 1,903 | N/A |
3/31/2024 | 10,558 | 2,144 | 1,694 | 2,164 | N/A |
12/31/2023 | 10,530 | 1,880 | 1,937 | 2,425 | N/A |
9/30/2023 | 10,434 | 2,139 | 1,349 | 2,114 | N/A |
6/30/2023 | 10,339 | 2,398 | 761 | 1,804 | N/A |
3/31/2023 | 9,951 | 2,239 | 773 | 1,823 | N/A |
12/31/2022 | 9,562 | 2,079 | 785 | 1,843 | N/A |
9/30/2022 | 9,403 | 1,995 | 1,068 | 1,829 | N/A |
6/30/2022 | 9,244 | 1,910 | 1,350 | 1,815 | N/A |
3/31/2022 | 8,921 | 2,156 | 1,410 | 1,911 | N/A |
12/31/2021 | 8,598 | 2,403 | 1,469 | 2,006 | N/A |
9/30/2021 | 8,131 | 2,340 | 1,487 | 2,001 | N/A |
6/30/2021 | 7,664 | 2,277 | 1,504 | 1,995 | N/A |
3/31/2021 | 7,008 | 2,035 | 1,351 | 1,726 | N/A |
12/31/2020 | 6,353 | 1,793 | 1,197 | 1,456 | N/A |
9/30/2020 | 6,306 | 1,558 | 1,020 | 1,400 | N/A |
6/30/2020 | 6,259 | 1,323 | 843 | 1,345 | N/A |
3/31/2020 | 6,425 | 1,237 | 790 | 1,324 | N/A |
12/31/2019 | 6,591 | 1,151 | 737 | 1,304 | N/A |
9/30/2019 | 6,450 | 1,048 | 1,177 | 1,661 | N/A |
6/30/2019 | 6,309 | 944 | 1,618 | 2,017 | N/A |
3/31/2019 | 6,134 | 828 | 1,326 | 1,713 | N/A |
12/31/2018 | 5,958 | 713 | 1,034 | 1,408 | N/A |
9/30/2018 | 5,845 | 642 | 535 | 898 | N/A |
6/30/2018 | 5,732 | 570 | 36 | 387 | N/A |
3/31/2018 | 5,251 | 516 | N/A | 553 | N/A |
12/31/2017 | 4,771 | 461 | N/A | 720 | N/A |
9/30/2017 | 4,480 | 413 | N/A | 708 | N/A |
6/30/2017 | 4,190 | 364 | N/A | 696 | N/A |
3/31/2017 | 3,943 | 317 | N/A | 736 | N/A |
12/31/2016 | 3,696 | 269 | N/A | 775 | N/A |
9/30/2016 | 3,573 | 241 | N/A | 807 | N/A |
6/30/2016 | 3,450 | 213 | N/A | 839 | N/A |
3/31/2016 | 3,348 | 197 | N/A | 668 | N/A |
12/31/2015 | 3,246 | 181 | N/A | 496 | N/A |
9/30/2015 | 3,158 | 187 | N/A | 439 | N/A |
6/30/2015 | 3,071 | 194 | N/A | 382 | N/A |
3/31/2015 | 3,097 | 185 | N/A | 430 | N/A |
12/31/2014 | 3,122 | 175 | N/A | 477 | N/A |
9/30/2014 | 3,040 | 150 | N/A | 602 | N/A |
6/30/2014 | 2,958 | 126 | N/A | 728 | N/A |
3/31/2014 | 2,808 | 113 | N/A | 760 | N/A |
12/31/2013 | 2,658 | 100 | N/A | 792 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: 512's forecast earnings growth (2.3% per year) is above the savings rate (2.3%).
Kazançlar ve Piyasa: 512's earnings (2.3% per year) are forecast to grow slower than the Hong Kong market (11.5% per year).
Yüksek Büyüme Kazançları: 512's earnings are forecast to grow, but not significantly.
Gelir ve Pazar: 512's revenue (6.2% per year) is forecast to grow slower than the Hong Kong market (7.7% per year).
Yüksek Büyüme Geliri: 512's revenue (6.2% per year) is forecast to grow slower than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: 512's Return on Equity is forecast to be low in 3 years time (13%).